Central Reinsurance (TPE:2851) Research & Development: NT$0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:2851 Central Reinsurance Corp TPE:2851
77 GF Score
Price NT$37.65
GF Value NT$28.70
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Central Reinsurance Research & Development?

Central Reinsurance TPE:2851 -1.05% 77 Research & Development is NT$0 Mil as of Dec. 2025. GuruFocus rates TPE:2851 with a GF Score™ of 77/100 and a GF Value™ of NT$28.70 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Central Reinsurance's Research & Development for the three months ended in Dec. 2025 was NT$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0 Mil.

Central Reinsurance  (TPE:2851) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Central Reinsurance Research & Development Related Terms

Central Reinsurance Research & Development Historical Data

* Premium members only.

The historical data trend for Central Reinsurance's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Reinsurance Research & Development Chart

Central Reinsurance Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Central Reinsurance Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:2851
77GF Score
Central Reinsurance Corp TPE:2851
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Central Reinsurance Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$0 Mil mean?
Central Reinsurance (TPE:2851) has a Research & Development of NT$0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Central Reinsurance and its competitors.
Is Central Reinsurance's Research & Development too high?
Central Reinsurance's current Research & Development is NT$0 Mil. Overall, Central Reinsurance has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Central Reinsurance's Research & Development compare to RGA and EG?
Central Reinsurance's Research & Development of NT$0 Mil can be compared against companies in the Insurance industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Insurance company?
A good Research & Development depends on the Insurance industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Central Reinsurance and its competitors. Central Reinsurance's current Research & Development is NT$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Reinsurance stock overvalued right now?
Based on GuruFocus' analysis, Central Reinsurance (TPE:2851) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$28.70, compared to a current price of NT$37.65 — trading 31.2% above its estimated fair value. The current Research & Development is NT$0 Mil. Central Reinsurance's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Central Reinsurance (TPE:2851), the current Research & Development is NT$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Central Reinsurance (TPE:2851) Overvalued in 2026?

Based on GuruFocus' analysis, Central Reinsurance stock appears to be overvalued. The current stock price of NT$37.65 is trading 31.2% above its estimated GF Value™ of NT$28.70. GuruFocus considers Central Reinsurance to be Significantly Overvalued.

Key valuation signals for TPE:2851:

  • Research & Development: NT$0 Mil
  • GF Value™: NT$28.70 vs. price of NT$37.65 (31.2% above fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the TPE:2851 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Central Reinsurance Business Description

Address Section 2, Nanjing East Road, 12th Floor, No. 53, Zhongshan District, Taipei, TWN, 10457
Central Reinsurance Corp is an insurance company providing a range of property and life inward and outward reinsurance services. Central Reinsurance offers reinsurance protection on non-life insurance businesses, including fire, marine and aviation, casualty, motor, engineering, and residential earthquake insurance; and life insurance business including life, personal accident, and health insurance. The main source of revenue for the company is premiums and commission income.
77GF Score

Get the complete analysis for TPE:2851

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$37.65
Price
NT$28.70
GF Value